OncoMatch

OncoMatch/Clinical Trials/NCT02290145

Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

Is NCT02290145 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TPF group for mouth neoplasms.

Phase 2RecruitingShanghai Jiao Tong University School of MedicineNCT02290145Data as of Jun 2026Location: China

Treatment: TPF groupThe purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

TPF group

Biomarker criteria

Required: CCND1 high expression (high)

Disease stage

Required: Stage III, IVA

Performance status

KARNOFSKY 61–100

Karnofsky performance status (KPS) >60

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: surgery

Exception: diagnostic biopsy

Surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy)

Cannot have received: radiation therapy

Previous radiotherapy

Cannot have received: cytotoxic chemotherapy

Previous chemotherapy

Lab requirements

Blood counts

white blood cell >3,000/mm3, hemoglobin >8g/L, platelet count >80,000/mm3

Kidney function

serum creatinine <1.5x ULN; creatinine clearance <30ml/min [excluded]

Liver function

ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN

Adequate hematologic function: white blood cell >3,000/mm3, hemoglobin>8g/L, platelet count>80,000/mm3. Hepatic function: ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN. Renal function: serum creatinine <1.5x ULN. Creatinine clearance <30ml/min [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT02290145 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Does this trial require CCND1?

Yes, CCND1 high expression is a required biomarker for enrollment.

What disease stage is eligible?

Stage III or IVA is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify